We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Reneuron Group Plc | RENE | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.05 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.05 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 17/6/2024 19:52 by thiopia £2m cash + a potential £1m claim on IP milestone gives almost 5p a share of Net Asset Value per Share ?Will be interesting what price the Cornerstone Investor will want though. |
Posted at 17/6/2024 08:47 by thiopia So they seem to be pursuing Business Plan 2.0 and have discussions ongoing with potential Cornerstone investors.In parallel if that doesn't work they are running a sale/disposal strategy and have prepared a 'teaser' document sent out to 749 !!! potential interested parties I think i'm reading that right. (Page 10) |
Posted at 20/5/2024 21:07 by thiopia 17 May 2024ReNeuron Group plc ("ReNeuron" or the "Company") Publication of Joint Administrators' Proposals ReNeuron Group plc (in administration) (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that Mark Smith and Stephen Cork of Cork Gully LLP, joint administrators of the Company and of its subsidiaries, ReNeuron Limited, ReNeuron (UK) Limited ReNeuron Holdings Limited (together the "Group") (all in administration) have issued their statement of proposals to the members and creditors of the Group in accordance with the Insolvency Act 1986 and the Insolvency Rules (the "Proposals"). The contents of the main body of the Proposals (without appendices) are set out below without material amendment. A hard copy of the Proposals, including appendices, can be obtained upon request by contacting the joint administrators using the details noted below. Purpose of the Administrations The purpose of the Administrations is to, in the first instance, rescue the Group as a going concern. Should the above not be achievable, the Joint Administrators will seek to achieve a better result for the Company's creditors as a whole than would be likely if the Group were wound up (without first being in Administration). Should both of the above objectives fail, the Joint Administrators will take steps to realise assets in order to make a distribution to one or more preferential creditors. Joint Administrators' strategy The Joint Administrators are progressing negotiations with investor(s) to allow for continuity of the Group's operations. Alternatively, an acquisition of all or part of the Group, or its business and/or assets, is also being explored. The Joint Administrators have sought to preserve value for a prospective investor or purchaser by retaining key employees and ensuring the continuation of critical services. |
Posted at 19/8/2023 23:02 by thiopia ("ReNeuron" or the "Company")Notice of Annual General Meeting ReNeuron Group plc (AIM: RENE) , a UK-based leader in stem cell derived exosome technologies , announces that the Notice of Annual General Meeting ("AGM") and Form of Proxy have today been posted to shareholders and will shortly be available on the investors section of the Company's website here . The AGM will be held at the offices of Covington & Burling LLP, Level 54, 22 Bishopsgate, London EC2N 4BQ on 22 August 2023 at 9.30 a.m. The Board welcomes the opportunity to invite shareholders to attend the AGM in person. Persons intending to attend and vote at the meeting in person will need a QR code to access the meeting venue. Such QR code will need to be displayed on a smartphone or similar device. A QR code will be able to be obtained in advance by emailing externalproxyqueries If shareholders are unable to attend the meeting in person, then they are encouraged to submit their votes by proxy by appointing the Chairman of the AGM as their proxy, so that their votes can be taken into account. Shareholders are also encouraged to submit any questions for the Chairman to info@reneuron.com at least 48 hours prior to the Meeting. Shareholders that are able to attend the AGM in person will also have an opportunity to ask questions at the Meeting. Where appropriate, questions and answers will be collated and later published on the Company's website at www.reneuron.com. The results of the proposed resolutions will be published on the Company website and announced via RNS as soon as practicable after the conclusion of the AGM. |
Posted at 18/5/2023 09:28 by thiopia Investor presentationReNeuron Group plc (AIM: RENE) , a UK-based leader in stem cell derived exosome technologies , will announce its preliminary results for the year ended 31 March 2023 on Thursday 25 May 2023. Investor Briefing Management will also be hosting a live online presentation relating to the preliminary results via the Investor Meet Company platform at 9:30am BST on Thursday 25 May 2023. The presentation is open to all existing and potential shareholders. Investors can sign up to Investor Meet Company for free and register for the presentation here: Investors who already follow ReNeuron on the Investor Meet Company platform will automatically be invited. Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards. |
Posted at 30/1/2023 13:53 by small crow Prices lowered on little volume and no reason. My take: good times coming soon for many bio/medical stocks. The patient investors know that but the impatient atm have the stock. Ergo ... |
Posted at 27/1/2023 23:29 by the stigologist From Investor Presentation in 2022Several ongoing Exosome collaborations. Must be a chance of getting one 'over the line' over next year surely ? |
Posted at 06/11/2022 17:36 by terminator101 That’s a lie mate, the reduced cash burn has already been taken into account in the assessment. Check the interims.This pedestrian fluff has a material uncertainty as to it being a going concern hanging over it like a sword of Damocles. The next fundraising will be brutal. 😳😳&# The Group is expected to incur further costs as it continues to develop its technologies through the research and pre-clinical development pathway. The operations of the Group are currently being financed from funds that have been raised from share placings, commercial partnerships and grants. The Group actively seeks further business development and commercial opportunities to support its ongoing development programmes. The Board places considerable emphasis on communication with shareholders, potential investors and other commercial organisations in order to maximise the chances of success in exploiting these opportunities. Following a strategic decision, it was announced in January 2022 that the internal development of the Group's hRPC programme would be halted, with existing resources refocused on the Group's exosome technology platform extending the companies cash runway. It is considered that this strategy provides the best opportunity to create increasing and sustainable shareholder value. Based on the above, the Directors expect that the Group's current financial resources will be sufficient to support the business until at least mid-2023 and the Directors continue to seek opportunities to secure further revenues / funding sufficient for the future needs of the business beyond mid-2023. The Directors therefore consider it appropriate to continue to adopt the going concern basis in the preparation of these financial statements. However, there is no guarantee that attempts to secure adequate additional revenues / funding on a timely basis will be successful and therefore this represents a material uncertainty, which may cast significant doubt about the Group's and Company's ability to continue as a going concern. These financial statements do not include the adjustments that would result if the Group were unable to continue as a going concern. |
Posted at 16/10/2022 07:28 by terminator101 Anyone investing in the pedestrian clowns running this pedestrian outfit needs their head examined, either that or they just want to lose money.What’s the bull case? At best they might get someone to buy into their “delivery platform” waffle. Honestly? The whole reason people take a risk on biotech and drug companies is because they might find the next wonder drug of cure for cancer. But this lot have given up on that dream. So the reward dosen’t seem that good for the risk you are taking. Then there’s the simple fact they need cash by mid 2023 at the latest. Given their record of failure and burning millions of pounds of investors cash, it’s unlikely that anyone will advance them any money, so you are looking at bucket shop brokers massive equity placing, and they will want a massive discount and loads of warrants to boot. If you think these clowns will make a massive scientific breakthrough before then, perhaps wait, but history suggests that knack all will be forthcoming. |
Posted at 22/8/2022 11:31 by terminator101 Guess investors weren't that impressed with the latest proactive interview huh. As per normal for this shower of pedestrian scientists nothing happening here quickly. Zzzzzzzzz |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
